Moderna initiates $2 billion senior notes offering to fund cancer vaccine development

Moderna is leveraging a 177% equity valuation increase to raise $2 billion in capital through senior notes. The proceeds are earmarked for the advancement of its oncology vaccine pipeline, signaling a strategic shift toward long-term R&D financing despite current market volatility.